KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2025)

Amneal Pharmaceuticals has reported Capital Leases over the past 9 years, most recently at $54.9 million for Q4 2025.

  • Quarterly results put Capital Leases at $54.9 million for Q4 2025, down 3.45% from a year ago — trailing twelve months through Dec 2025 was $54.9 million (down 3.45% YoY), and the annual figure for FY2025 was $54.9 million, down 3.45%.
  • Capital Leases for Q4 2025 was $54.9 million at Amneal Pharmaceuticals, down from $55.7 million in the prior quarter.
  • Over the last five years, Capital Leases for AMRX hit a ceiling of $61.9 million in Q1 2021 and a floor of $54.9 million in Q4 2025.
  • Median Capital Leases over the past 5 years was $59.1 million (2023), compared with a mean of $58.7 million.
  • Biggest five-year swings in Capital Leases: skyrocketed 2912.55% in 2021 and later fell 3.75% in 2025.
  • Amneal Pharmaceuticals' Capital Leases stood at $60.3 million in 2021, then grew by 0.86% to $60.8 million in 2022, then dropped by 3.63% to $58.6 million in 2023, then fell by 2.86% to $56.9 million in 2024, then fell by 3.45% to $54.9 million in 2025.
  • The last three reported values for Capital Leases were $54.9 million (Q4 2025), $55.7 million (Q3 2025), and $56.0 million (Q2 2025) per Business Quant data.